Overview
Vitamin D supplementation provides the secosteroid hormone precursor that activates the vitamin D receptor (VDR) — a nuclear receptor expressed in virtually every immune cell, enterocyte, and neuron. Vitamin D deficiency is pandemic (estimated 1 billion people worldwide) and intersects with autoimmune, neurological, metabolic, and gastrointestinal diseases through immunomodulatory, barrier-protective, and neuroendocrine pathways.
> Clinical disclaimer: Vitamin D supplementation should be guided by measured 25(OH)D levels. Target 40-60 ng/mL (100-150 nmol/L) for autoimmune and neurological conditions. Doses above 4000 IU/day require monitoring to avoid hypercalcemia. Vitamin D is fat-soluble and accumulates; toxicity is rare below 10,000 IU/day but possible with impaired renal function. All dosing decisions require clinical supervision.
—-
Mechanism of Action
Vitamin D operates through three primary pathways:
- Immune modulation: VDR activation on T cells promotes Treg differentiation (IL-10, TGF-beta), suppresses Th17 polarization (IL-17, IL-22), and induces tolerogenic dendritic cells. This rebalances the Th17/Treg axis disrupted in autoimmune diseases.
- Barrier integrity: VDR in intestinal epithelium upregulates tight junction proteins (claudin-2, occludin, ZO-1) and antimicrobial peptides (cathelicidin LL-37, beta-defensin 2). Deficiency increases intestinal permeability.
- Neuroendocrine regulation: VDR in hippocampal and prefrontal neurons activates TPH2 (tryptophan hydroxylase 2) transcription, directly increasing brain serotonin synthesis. Also upregulates BDNF and modulates HPA axis reactivity.
—-
Dosage and Administration
| Condition | Dose | Form | Duration | Notes |
|---|---|---|---|---|
| multiple sclerosis | 4000 IU/day (up to 7000 IU/day in trials) | Cholecalciferol (D3) | Ongoing | Target 25(OH)D 40-60 ng/mL; adjunct to DMT |
| hashimotos thyroiditis | 2000-4000 IU/day | Cholecalciferol (D3) | Ongoing | Combine with selenium supplementation 200 ug/day |
| inflammatory bowel disease | 2000-4000 IU/day | Cholecalciferol (D3) | Ongoing | Higher doses during flares; monitor absorption |
| depression | 2000-4000 IU/day | Cholecalciferol (D3) | 8-12 weeks minimum | Best evidence in documented deficiency |
| pcos | 2000-4000 IU/day | Cholecalciferol (D3) | 12+ weeks | Combine with probiotics general for synergistic metabolic effect |
General notes:
- Cholecalciferol (D3) is preferred over ergocalciferol (D2) for efficacy and half-life
- Take with a fat-containing meal to optimize absorption
- Loading doses (50,000 IU weekly for 8 weeks) appropriate for severe deficiency (<20 ng/mL)
- Maintenance range: 2000-4000 IU/day for most adults
—-
Monitoring
- 25(OH)D (calcidiol): The standard monitoring biomarker. Measure at baseline, 8-12 weeks, then every 6 months.
- Deficiency: <20 ng/mL (<50 nmol/L)
- Insufficiency: 20-30 ng/mL (50-75 nmol/L)
- Optimal for autoimmune/neurological: 40-60 ng/mL (100-150 nmol/L)
- Toxicity concern: >100 ng/mL (>250 nmol/L)
- Calcium (serum): Check at baseline and if dosing >4000 IU/day; hypercalcemia is the primary toxicity
- PTH (parathyroid hormone): Elevated PTH with low 25(OH)D confirms functional deficiency
- 1,25(OH)2D (calcitriol): NOT a routine monitoring marker (short half-life, tightly regulated); useful only in granulomatous disease or renal failure
—-
Contraindications and Risks
- Hypercalcemia: Primary toxicity risk; more likely with granulomatous diseases (sarcoidosis, tuberculosis) where unregulated 1-alpha-hydroxylase converts 25(OH)D to active calcitriol
- Renal impairment: Reduced calcitriol clearance increases hypercalcemia risk; dose adjustment required
- Hyperphosphatemia: May compound in CKD
- Drug interactions: Corticosteroids reduce vitamin D efficacy; thiazide diuretics increase calcium retention
- Fat malabsorption: IBD, celiac, or short-bowel patients may require higher doses or intramuscular administration
—-
Connections
Entities: selenium, zinc, iron
Concepts: immune balance, intestinal permeability, gut brain axis, neuroinflammation, dysbiosis
Related interventions: selenium supplementation (synergistic in Hashimoto's), probiotics general (synergistic in PCOS), zinc supplementation (complementary immune support)
Signatures: multiple sclerosis, hashimotos thyroiditis, inflammatory bowel disease, depression, pcos